United States Court of Appeals for the First Circuit · 2019-06-27
15usc78j: author: Astra2 · not independently reviewed
Case and law context
Role: applied; posture: private Biogen securities class action; Rule 12(b)(6) dismissal under PSLRA; claim-preclusion issue expressly reserved; result: claimant-lost; claim:
Uncertainty
None recorded
Misfit
Corporate-scienter alternative analysis is not encoded as a separate corporate finding. The PSLRA strong-inference gate lives under scienter because the DSL cannot attach a case block to the law's private-pleading constraint.
B · Case × element grid
Top-level elements follow claim order in panels of up to six elements. Case rows repeat across panels. Every recorded block retains its holding and basis; multiple blocks are not merged into a case-level verdict. ✓ satisfied · ✗ not satisfied · ○ not reached · · not addressed. Muted blocks are not counted. Sub-element evidence remains on case and element pages.
Elements 1–6 of 12
| Case | Statutory commerce, mails, or exchange facility | Section 78j(b) rulemaking hook | Materially false statement or misleading half-truth | Importance to a reasonable investor | Intent to deceive, manipulate, or defraud | Connection with a covered securities or swap transaction |
|---|---|---|---|---|---|---|
| Metzler Asset Mgmt. GMBH v. Kingsley — 928 F.3d 151 (2019) · United States Court of Appeals for the First Circuit · 2019 (15usc78j: author: Astra2 · not independently reviewed) | · not addressed | · not addressed | · not addressed | · not addressed | · not addressed |
Elements 7–12 of 12
| Case | Private plaintiff's purchaser or seller status | Private investor transaction causation | Actual economic loss in private damages action | Causal connection between fraud and economic loss | Fraudulent scheme or deceptive course of business | Additional criminal mental-state requirement |
|---|---|---|---|---|---|---|
| Metzler Asset Mgmt. GMBH v. Kingsley — 928 F.3d 151 (2019) · United States Court of Appeals for the First Circuit · 2019 (15usc78j: author: Astra2 · not independently reviewed) | · not addressed | · not addressed | · not addressed | · not addressed | · not addressed | · not addressed |
Instances and excluded annotation blocks
| Case | Element | Holding and scope | Pattern | Exact source quotations |
|---|---|---|---|---|
| Metzler Asset Mgmt. GMBH v. Kingsley — 928 F.3d 151 (2019) · United States Court of Appeals for the First Circuit · 2019 — not · pleaded (15usc78j: author: Astra2 · not independently reviewed) | Intent to deceive, manipulate, or defraud | not Counted merits instance applied / merits basis: pleaded; party: individual executives; count: safety-profile statements; subject: party=individual executives; count=safety-profile statements The research report did not contradict the limited effectiveness/data statement; the later statement was evaluated against the already revised safety disclosures. Plausible misleadingness was assumed, not decided. | disclosure-context/drug-safety-research | The complaint alleges that Sandrock made this statement before Biogen's October announcement of the PML-related death, and the plaintiffs do not contend that any of the individual defendants knew about that death before Sandrock made this statement. The plaintiffs nevertheless contend that the District Court erred in concluding that the complaint failed adequately to allege that Sandrock made the statement with the "intentional or willful" design to deceive investors.Source: docroot/ir/caselaw/f3d_928.jsonl#/f3d/928/0151-01; Unicode character offsets [17665:18137] (end exclusive); SHA-256 f61a6ef7f990d3d81d71d8fdc66c73ed8ee6cacf6431d1e8699d0b20442af578.To make this case, the plaintiffs point out that, in August and September of 2014, Dr. Ben Thrower, the medical director at the Shepherd Center in Atlanta, notified Keith Ferguson, the company's senior sales director, and Eric Hall, the medical science liaison for Biogen, that his research showed that patients who were taking Tecfidera had a higher risk of developing low lymphocyte counts than Biogen had originally disclosed. The complaint further alleges that, for this reason, Dr. Thrower chose to discontinue Tecfidera prescriptions for approximately 200 of his patients and to stop issuing new prescriptions for the drug. The complaint also alleges that he told Ferguson and Hall about this development.Source: docroot/ir/caselaw/f3d_928.jsonl#/f3d/928/0151-01; Unicode character offsets [18138:18849] (end exclusive); SHA-256 f61a6ef7f990d3d81d71d8fdc66c73ed8ee6cacf6431d1e8699d0b20442af578.By April of 2015, according to the complaint, Biogen had already disclosed the PML death and updated the drug's label to account for the increased understanding of its risk.Source: docroot/ir/caselaw/f3d_928.jsonl#/f3d/928/0151-01; Unicode character offsets [20345:20518] (end exclusive); SHA-256 f61a6ef7f990d3d81d71d8fdc66c73ed8ee6cacf6431d1e8699d0b20442af578."For an inference of scienter to be strong, 'a reasonable person would [have to] deem [it] cogent and at least as compelling as any opposing inference one could draw from the facts alleged.' "Source: docroot/ir/caselaw/f3d_928.jsonl#/f3d/928/0151-01; Unicode character offsets [14995:15187] (end exclusive); SHA-256 f61a6ef7f990d3d81d71d8fdc66c73ed8ee6cacf6431d1e8699d0b20442af578.And thus, the allegations regarding Sandrock fail to establish a "strong inference" of scienter as to even him, let alone as to any individual defendant.Source: docroot/ir/caselaw/f3d_928.jsonl#/f3d/928/0151-01; Unicode character offsets [19829:19982] (end exclusive); SHA-256 f61a6ef7f990d3d81d71d8fdc66c73ed8ee6cacf6431d1e8699d0b20442af578. |
| Metzler Asset Mgmt. GMBH v. Kingsley — 928 F.3d 151 (2019) · United States Court of Appeals for the First Circuit · 2019 — not · pleaded (15usc78j: author: Astra2 · not independently reviewed) | Intent to deceive, manipulate, or defraud | not Counted merits instance applied / merits basis: pleaded; party: Stuart Kingsley; count: usage-rate statements; subject: party=Stuart Kingsley; count=usage-rate statements The missing information is what Kingsley learned from monitoring metrics and whether it conflicted with his public statements. Access to metrics plus confidential witnesses several levels below management did not supply the strong inference. | disclosure-context/usage-rates-and-management-metrics | We first address the January 29, 2015 statement by Kingsley that "Tecfidera [was] on track to become the most prescribed therapy for MS worldwide." The plaintiffs argue that this statement was misleading and creates the "strong inference" of scienter on Kingsley's part, because at the time of the statement, Kingsley knew about both the PML death and about Tecfidera's declining sales and discontinuation rates.Source: docroot/ir/caselaw/f3d_928.jsonl#/f3d/928/0151-01; Unicode character offsets [22023:22435] (end exclusive); SHA-256 f61a6ef7f990d3d81d71d8fdc66c73ed8ee6cacf6431d1e8699d0b20442af578.At the time that Kingsley made the statement, however, Biogen had already disclosed to the public the news of the PML death, had already changed the drug's label, had already publicized that it expected the drug's growth rate to "slow," and had already disclosed that the drug's discontinuation rates were higher than expected.Source: docroot/ir/caselaw/f3d_928.jsonl#/f3d/928/0151-01; Unicode character offsets [22436:22763] (end exclusive); SHA-256 f61a6ef7f990d3d81d71d8fdc66c73ed8ee6cacf6431d1e8699d0b20442af578.Yet, the complaint alleges no facts that are illuminating in that regard.Source: docroot/ir/caselaw/f3d_928.jsonl#/f3d/928/0151-01; Unicode character offsets [27496:27569] (end exclusive); SHA-256 f61a6ef7f990d3d81d71d8fdc66c73ed8ee6cacf6431d1e8699d0b20442af578.But, we find no basis for concluding that any of these statements permit us to infer the necessary intent to deceive that could suffice to create the "strong inference" of scienter that the PSLRA requires.Source: docroot/ir/caselaw/f3d_928.jsonl#/f3d/928/0151-01; Unicode character offsets [21710:21915] (end exclusive); SHA-256 f61a6ef7f990d3d81d71d8fdc66c73ed8ee6cacf6431d1e8699d0b20442af578. |
Court interpretations recorded from this case
interpretation
"For an inference of scienter to be strong, 'a reasonable person would [have to] deem [it] cogent and at least as compelling as any opposing inference one could draw from the facts alleged.' "
Metzler Asset Mgmt. GMBH v. Kingsley — 928 F.3d 151 (2019) · United States Court of Appeals for the First Circuit · 2019 (15usc78j: author: Astra2 · not independently reviewed)
"For an inference of scienter to be strong, 'a reasonable person would [have to] deem [it] cogent and at least as compelling as any opposing inference one could draw from the facts alleged.' "Source:
docroot/ir/caselaw/f3d_928.jsonl#/f3d/928/0151-01; Unicode character offsets [14995:15187] (end exclusive); SHA-256 f61a6ef7f990d3d81d71d8fdc66c73ed8ee6cacf6431d1e8699d0b20442af578.Pleading specificity and strong inference govern private complaint sufficiency Metzler applies PSLRA/Tellabs to dismiss insufficient scienter allegations even assuming statements plausibly misleading. Pleading is not proof at trial.